Guggenheim Capital LLC lowered its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 62.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,633 shares of the company's stock after selling 91,055 shares during the quarter. Guggenheim Capital LLC's holdings in Moderna were worth $2,230,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. Geode Capital Management LLC increased its position in Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after buying an additional 171,774 shares in the last quarter. Invesco Ltd. raised its stake in shares of Moderna by 24.3% in the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after buying an additional 979,858 shares during the period. Norges Bank bought a new position in shares of Moderna during the 4th quarter valued at approximately $163,833,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Moderna by 9.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after acquiring an additional 211,426 shares during the period. Institutional investors own 75.33% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on MRNA shares. UBS Group reduced their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Evercore ISI set a $50.00 price target on Moderna in a research note on Friday, February 14th. JPMorgan Chase & Co. decreased their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Friday, March 21st. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and decreased their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and an average target price of $58.70.
Get Our Latest Report on Moderna
Moderna Stock Down 1.9 %
NASDAQ MRNA opened at $24.72 on Friday. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The firm has a market capitalization of $9.56 billion, a price-to-earnings ratio of -2.66 and a beta of 2.23. The company has a fifty day moving average of $30.84 and a two-hundred day moving average of $39.64.
Moderna Profile
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
